Enanta Pharmaceuticals, a biotech focused on developing small molecule drugs to use against hepatitis C, raised $56 million by offering 4.0 million shares at $14, the low end of the range of $14 to $16. Enanta Pharmaceuticals plans to list on the NASDAQ under the symbol ENTA. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.
